Attovia Therapeutics (NASDAQ:ATTO) Director Colin Walsh Buys 85,000 Shares

Posted by Scott Moore on Aug 15th, 2026

Attovia Therapeutics, Inc. (NASDAQ:ATTO – Get Free Report) Director Colin Walsh bought 85,000 shares of the company’s stock in a transaction dated Wednesday, August 5th. The stock was purchased at an average cost of $21.00 per share, for a total transaction of $1,785,000.00. Following the completion of the acquisition, the director owned 85,000 shares in the company, valued at $1,785,000. This trade represents a ∞ increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Colin Walsh also recently made the following trade(s):

On Wednesday, August 5th, Colin Walsh sold 105,807 shares of Attovia Therapeutics stock. The shares were sold at an average price of $21.28, for a total transaction of $2,251,572.96.
On Thursday, August 6th, Colin Walsh bought 500,000 shares of Attovia Therapeutics stock. The shares were acquired at an average price of $17.00 per share, with a total value of $8,500,000.00.

Attovia Therapeutics Trading Up 3.5%

Shares of NASDAQ ATTO opened at $19.86 on Friday. Attovia Therapeutics, Inc. has a 12 month low of $16.15 and a 12 month high of $22.79.

Hedge Funds Weigh In On Attovia Therapeutics

An institutional investor recently raised its stake in Attovia Therapeutics stock. BlackRock Inc. grew its stake in Attovia Therapeutics, Inc. (NASDAQ:ATTO – Free Report) by 23.4% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 164,358 shares of the company’s stock after purchasing an additional 31,189 shares during the quarter. BlackRock Inc.’s holdings in Attovia Therapeutics were worth $317,000 as of its most recent SEC filing.

About Attovia Therapeutics

(Get Free Report)

Attovia Therapeutics, Inc (NASDAQ: ATTO) is a clinical-stage biopharmaceutical company developing antibody-based medicines for inflammatory and immune-mediated diseases. The company’s research is focused on creating differentiated biologic therapies intended to address significant unmet medical needs.

Attovia uses proprietary antibody-engineering technologies to discover and develop therapeutic candidates, including multispecific antibodies designed to modulate disease-related biological pathways.